Skip to main content

6-K

Cybin Inc. (HELP)

6-K 2023-10-13 For: 2023-10-13
View Original
Added on April 08, 2026

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2023.

Commission File Number: 001-40673

Cybin Inc. (Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F □ Form 40-F ⊠

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYBIN INC.
(Registrant)
Date: October 13, 2023 By: /s/ Doug Drysdale
Name: Doug Drysdale
Title: Chief Executive Officer

EXHIBIT INDEX

99.1 Report of Voting Results

Document

image_0a.jpg

REPORT OF VOTING RESULTS SECTION 11.3 OF NATIONAL INSTRUMENT 51-102

In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual and special meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. (“Cybin”) held on October 12, 2023 (the “Meeting”).

There were 66 Shareholders represented in person or by proxy at the Meeting holding 91,903,025 common shares, representing 39.16% of Cybin’s total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by a ballot vote.

1.    Acquisition Resolution

The acquisition of Small Pharma Inc. (“Small Pharma”), by way of a proposed plan of arrangement under the Business Corporations Act (British Columbia), pursuant to the terms and subject to the conditions of the arrangement agreement between Cybin and Small Pharma, dated August 28, 2023, was approved. Voting results are set out below:

Votes For Votes Against
# % # %
43,199,295 99.410 256,200 0.590

2.    Appointment of Auditor

Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:

Votes For Votes Withheld
# % # %
91,252,133 99.292 650,891 0.708

3.    Number of Directors

The special resolution to set the number of directors of Cybin at six (6) was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes For Votes Against
# % # %
90,712,567 98.705 1,190,458 1.295

4.    Election of Directors

Each of the nominees for election as director listed in Cybin’s management information circular dated September 13, 2023 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

Votes For Votes Withheld
# % # %
Theresa Firestone 42,976,922 98.899 478,573 1.101
Grant Froese 43,022,128 99.003 433,368 0.997
Paul Glavine 43,012,466 98.980 443,030 1.020
Eric Hoskins 42,906,846 98.737 548,649 1.263
Mark Lawson 42,971,117 98.885 484,379 1.115
Eric So 39,668,729 91.286 3,786,767 8.714

49784830.3

  • 2 -